Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico

Parasites and Vectors

Volumn 6, Issue 1, 2013, Pages

  Gonzalez Ceron, Lilia ^a   Mu, Jianbing ^b   Santillán, Frida ^a   Joy, Deirdre ^b   Sandoval, Marco A ^a   Camas, Gerardo ^a   Su, Xinzhuan ^b   Choy, Elena V ^a   Torreblanca, Rene ^c  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Ministry of Health   (Mexico)

Author keywords

Epidemiology; Genetic homology; Hypnozoite; Plasmodium vivax; Relapse; Southern Mexico

Indexed keywords

CSP PROTEIN; MSP3A PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; DISEASE DURATION; DISEASE TRANSMISSION; DNA EXTRACTION; FOLLOW UP; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MEXICO; MICROSATELLITE MARKER; PLASMODIUM VIVAX MALARIA; RECURRENT INFECTION; REINFECTION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEASON; SEQUENCE HOMOLOGY; TEMPORAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANIMALS; BLOOD; CHILD; DNA FINGERPRINTING; DNA, PROTOZOAN; FEMALE; GENOTYPE; HUMANS; MALARIA, VIVAX; MALE; MEXICO; MICROSATELLITE REPEATS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PLASMODIUM VIVAX; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECURRENCE; YOUNG ADULT;

PLASMODIUM VIVAX;

EID: 84876180063     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-6-109     Document Type: Article

References (55)

1. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades, Dirección general de epidemiología: Secretaria de Salud México http://www.dgepi.salud.gob.mx/2010/plantilla/intd-boletin. html 23336544
2. La malaria en México. Progresos y desafíos hacia su eliminación Challenges and progress in the elimination of malaria in Mexico [Challenges and progress in the elimination of malaria in Mexico. Betanzos AF, Bol Med Hosp Infant Mex 2011 68 2 159 168
3. History of the discovery of the malaria parasites and their vectors. Cox FE, Parasit Vectors 2010 3 1 5 10.1186/1756-3305-3-5 20205846
4. Primaquine therapy for malaria. Baird JK, Hoffman SL, Clin Infect Dis 2004 39 9 1336 1345 10.1086/424663 15494911 (Pubitemid 39458520)
5. Determinants of relapse periodicity in Plasmodium vivax malaria. White NJ, Malar J 2011 10 297 10.1186/1475-2875-10-297 21989376
6. Experimental, therapeutic and natural transmission of Plasmodium vivax tertian malaria: scientific and anecdotal data on the history of Dutch malaria studies. Verhave JP, Parasit Vectors 2013 6 1 19 10.1186/1756-3305-6-19 23332002
7. Letter: Malarial relapse mechanism. Contacos PG, Collins WE, Trans R Soc Trop Med Hyg 1973 67 4 617 618 10.1016/0035-9203(73)90104-1 4206527
8. Studies on the characterization of Plasmodium vivax strains from Central America. Contacos PG, Collins WE, Jeffery GM, Krotoski WA, Howard WA, Am J Trop Med Hyg 1972 21 5 707 712 4627547
9. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ, Am J Trop Med Hyg 2006 75 402 415 16968913 (Pubitemid 46941297)
10. Guidelines for malaria treatment Geneva, WHO, Second 2010 http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html
11. Prevention and treatment of vivax malaria. Baird JK, Schwartz E, Hoffman SL, Curr Infect Dis Rep 2007 9 1 39 46 10.1007/s11908-007-0021-4 17254503 (Pubitemid 46242411)
12. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Goller JL, Jolley D, Ringwald P, Biggs BA, Am J Trop Med Hyg 2007 76 2 203 207 17297026 (Pubitemid 351627764)
13. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. Spudick JM, Garcia LS, Graham DM, Haake DA, J Clin Microbiol 2005 43 2 978 981 10.1128/JCM.43.2.978-981.2005 15695723 (Pubitemid 40256077)
14. Secretaria de Salud, NORMA Oficial Mexicana NOM-032-SSA2-2002, Para la vigilancia epidemiológica, prevención y control de enfermedades transmitidas por vector México 2002 http://www.salud.gob.mx/unidades/cdi/ nom/032ssa202.html
15. Evaluation of an alternative scheme of treatment for the control of malaria. Mendez Galvan JF, Guerrero Alvarado J, Gonalez Mora M, Perez Landa M, Quintero Cabanillas R, Salud Publica Mex 1984 26 6 561 572 6393363
16. WHO, World Malaria Report Geneva 2009 http://www.who.int/malaria/world- malaria-report-2009/en/index.html
17. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. Craig AA, Kain KC, J Infect Dis 1996 174 2 373 379 10.1093/infdis/174.2.373 8699069 (Pubitemid 26251425)
18. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q, J Infect Dis 2007 195 7 934 941 10.1086/512242 17330782 (Pubitemid 46452097)
19. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, J Infect Dis 2007 195 7 927 933 10.1086/512241 17330781 (Pubitemid 46452096)
20. Differential susceptibilities of Anopheles albimanus and Anopheles pseudopunctipennis to infections with coindigenous Plasmodium vivax variants VK210 and VK247 in southern Mexico. Gonzalez-Ceron L, Rodriguez MH, Nettel JC, Villarreal C, Kain KC, Hernandez JE, Infect Immun 1999 67 1 410 412 9864243 (Pubitemid 29021676)
21. Plasmodium vivax: ookinete destruction and oocyst development arrest are responsible for Anopheles albimanus resistance to circumsporozoite phenotype VK247 parasites. Gonzalez-Ceron L, Rodriguez MH, Santillan F, Chavez B, Nettel JA, Hernandez-Avila JE, Kain KC, Exp Parasitol 2001 98 3 152 161 10.1006/expr.2001.4626 11527438 (Pubitemid 32835823)
22. Plasmodium vivax: impaired escape of Vk210 phenotype ookinetes from the midgut blood bolus of Anopheles pseudopunctipennis. Gonzalez-Ceron L, Rodriguez MH, Chavez-Munguia B, Santillan F, Nettel JA, Hernandez-Avila JE, Exp Parasitol 2007 115 1 59 67 10.1016/j.exppara.2006.06.001 16875689
23. Merozoite surface protein-3alpha is a reliable marker for population genetic analysis of Plasmodium vivax. Zakeri S, Barjesteh H, Djadid ND, Malar J 2006 5 53 10.1186/1475-2875-5-53 16817951 (Pubitemid 44490964)
24. Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. Galinski MR, Corredor-Medina C, Povoa M, Crosby J, Ingravallo P, Barnwell JW, Mol Biochem Parasitol 1999 101 1-2 131 147 10413049 (Pubitemid 29257847)
25. Extensive polymorphism in the Plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domains. Rayner JC, Corredor V, Feldman D, Ingravallo P, Iderabdullah F, Galinski MR, Barnwell JW, Parasitology 2002 125 Pt 5 393 405 12458823 (Pubitemid 35397376)
26. Genetic diversity and multiple infections of Plasmodium vivax malaria in Western Thailand. Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, Zhou G, Chen H, Yan G, Sattabongkot J, Am J Trop Med Hyg 2003 68 5 613 619 12812356 (Pubitemid 38240504)
27. Local adaptation and vector-mediated population structure in Plasmodium vivax malaria. Joy DA, Gonzalez-Ceron L, Carlton JM, Gueye A, Fay M, McCutchan TF, Su XZ, Mol Biol Evol 2008 25 6 1245 1252 10.1093/molbev/msn073 18385220
28. Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens. Kain KC, Brown AE, Webster HK, Wirtz RA, Keystone JS, Rodriguez MH, Kinahan J, Rowland M, Lanar DE, J Clin Microbiol 1992 30 7 1863 1866 1629344
29. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Imwong M, Pukrittayakamee S, Gruner AC, Renia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, Malar J 2005 4 1 20 10.1186/1475-2875-4-20 15854233 (Pubitemid 40918738)
30. Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: global and local diversity. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP, Am J Trop Med Hyg 1999 61 4 518 525 10548283 (Pubitemid 29506329)
31. Genetic diversity of Plasmodium vivax in Kolkata. Kim JR, Imwong M, Nandy A, Chotivanich K, Nontprasert A, Tonomsing N, Maji A, Addy M, Day NP, White NJ, India. Malar J 2006 5 71 10.1186/1475-2875-5-71 (Pubitemid 44357748)
32. Plasmodium vivax polymorphism in a clinical drug trial. Adak T, Valecha N, Sharma VP, Clin Diagn Lab Immunol 2001 8 5 891 894 11527798 (Pubitemid 32868302)
33. GenAlEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research - an update. Peakall R, Smouse PE, Bioinformatics 2012 28 19 2537 2539 10.1093/bioinformatics/bts460 22820204
34. Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. Koepfli C, Mueller I, Marfurt J, Goroti M, Sie A, Oa O, Genton B, Beck HP, Felger I, J Infect Dis 2009 199 7 1074 1080 10.1086/597303 19275476
35. Patterns of Plasmodium vivax recurrence in a high-incidence coastal area of El Salvador, C. Mason J, A. Am J Trop Med Hyg 1975 24 4 581 585
36. Natural relapses in vivax malaria induced by Anopheles mosquitoes. Hulden L, Heliovaara K, Malar J 2008 7 64 10.1186/1475-2875-7-64 18430203 (Pubitemid 351667563)
37. The participation of secondary clinical episodes in the epidemiology of vivax malaria during pre- and post-implementation of focal control in the state of Oaxaca. Rodriguez MH, Betanzos-Reyes AF, Hernandez-Avila JE, Mendez-Galvan JF, Danis-Lozano R, Altamirano-Jimenez A, Mexico. Am J Trop Med Hyg 2009 80 6 889 895
38. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A, Schopflin S, Stanisic D, Betuela I, Blood-Zikursh M, PLoS One 2010 5 2 9047 10.1371/journal.pone.0009047 20140220
39. An outbreak of Plasmodium vivax malaria in Far North Queensland, 2002. Hanna JN, Ritchie SA, Eisen DP, Cooper RD, Brookes DL, Montgomery BL, Med J Aust 2004 180 1 24 28 14709124 (Pubitemid 38049310)
40. A closer look at multiple-clone Plasmodium vivax infections: detection methods, prevalence and consequences. Havryliuk T, Ferreira MU, Mem Inst Oswaldo Cruz 2009 104 1 67 73 19274379
41. Plan to improve malaria control towards its elimination in Mesoamerica. Rodriguez MH, Betanzos-Reyes AF, Salud Publica Mex 2011 53 3 333 348 22344378
42. WHO, Malaria elimination. A field manual for low and moderate endemic countries Geneva 2007 http://whqlibdoc.who.int/publications/2007/9789241596084- eng.pdf
43. Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. Kim JR, Nandy A, Maji AK, Addy M, Dondorp AM, Day NP, Pukrittayakamee S, White NJ, Imwong M, PLoS One 2012 7 7 39645 10.1371/journal.pone.0039645 22808048
44. The hypnozoite and relapse in primate malaria. Cogswell FB, Clin Microbiol Rev 1992 5 1 26 35 1735093
45. High dose of primaquine in primaquine resistant vivax malaria. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T, Trans R Soc Trop Med Hyg 1994 88 2 218 219 10.1016/0035-9203(94)90305-0 8036680 (Pubitemid 24139695)
46. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days. Carmona-Fonseca J, Maestre A, Acta Trop 2009 112 2 188 192 10.1016/j.actatropica.2009.07.024 19653988
47. Determination of the Plasmodium vivax relapse pattern in Camopi. Hanf M, Stephani A, Basurko C, Nacher M, Carme B, French Guiana Malar J 2009 8 278 10.1186/1475-2875-8-278
48. Frequency of malaria relapse due to Plasmodium vivax in a non-endemic region (Sao Paulo, Brazil). Boulos M, Amato Neto V, Dutra AP, Di Santi SM, Shiroma M, Rev Inst Med Trop Sao Paulo 1991 33 2 143 146 10.1590/S0036- 46651991000200009 1844384
49. Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU, Am J Trop Med Hyg 2009 81 6 961 968 10.4269/ajtmh.2009.09-0337 19996423
50. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. Coatney GR, Cooper WC, Young MD, J Natl Malar Soc 1950 9 4 381 396 14804098
51. Malaria. White NJ, Manson's Tropical Diseases London: WB Sounders, Cook GC, Zumla AI, 21 2003 1205 1295 23613602
52. High frequency of genetic diversity of Plasmodium vivax field isolates in Myanmar. Moon SU, Lee HW, Kim JY, Na BK, Cho SH, Lin K, Sohn WM, Kim TS, Acta Trop 2009 109 1 30 36 10.1016/j.actatropica.2008.09.006 18851938
53. Estimating the relapse risk of Plasmodium vivax in Iran under national chemotherapy scheme using a novel method. Haghdoost AA, Mazhari S, Bahaadini K, J Vector Borne Dis 2006 43 4 168 172 17175701 (Pubitemid 44901459)
54. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Mangoni AA, Jackson SH, Br J Clin Pharmacol 2004 57 1 6 14 14678335 (Pubitemid 38067945)
55. Malaria attack: a very late relapse due to Plasmodium vivax. Maslin J, Cuguillere A, Bonnet D, Martet G, Bull Soc Pathol Exot 1997 90 1 25 26 9264744 (Pubitemid 127365951)